Assembly Biosciences Ditches HBV Program, Cuts 45% Workforce

Ticker: ASMB · Form: 8-K · Filed: 2024-06-03T00:00:00.000Z

Sentiment: mixed

Topics: strategic-shift, layoffs, drug-discontinuation, pipeline-change

TL;DR

Assembly Bio is killing its Hep B drug and laying off nearly half its staff to focus on gut bugs. Cash saved.

AI Summary

Assembly Biosciences, Inc. announced on May 29, 2024, a strategic decision to discontinue its Hepatitis B virus (HBV) program, including its lead drug candidate vebicorvir. This move is part of a broader strategic realignment to focus on its microbiome-based therapies for infectious diseases. The company will also reduce its workforce by approximately 45% to conserve cash and extend its operating runway.

Why It Matters

This pivot away from a key drug program and significant layoffs indicate a major strategic shift for Assembly Biosciences, potentially impacting its future development pipeline and financial stability.

Risk Assessment

Risk Level: high — Discontinuing a drug program and significant workforce reduction signals substantial challenges and a high degree of uncertainty for the company's future prospects.

Key Numbers

Key Players & Entities

FAQ

What is the primary reason for discontinuing the HBV program?

The company is discontinuing the HBV program as part of a strategic realignment to focus on its microbiome-based therapies for infectious diseases.

What specific drug candidate is affected by this decision?

The lead drug candidate vebicorvir, which was part of the HBV program, is being discontinued.

What is the expected impact of the workforce reduction?

The company expects to reduce its workforce by approximately 45%, which is intended to conserve cash and extend its operating runway.

What is the new strategic focus for Assembly Biosciences?

The company is shifting its focus to its microbiome-based therapies for infectious diseases.

When was the earliest event reported in this filing?

The earliest event reported was on May 29, 2024.

From the Filing

0000950170-24-067951.txt : 20240603 0000950170-24-067951.hdr.sgml : 20240603 20240603160512 ACCESSION NUMBER: 0000950170-24-067951 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240529 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240603 DATE AS OF CHANGE: 20240603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 241013575 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20240529.htm 8-K 8-K 0001426800 false 0001426800 2024-05-29 2024-05-29     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. (the “Company”) 2024 Annual Meeting held on May 29, 2024 (the “Annual Meeting”), the Company’s stockholders approved the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan

View on Read The Filing